The role of the circadian clock in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 15, Issue 1, 2013, Pages

  Gibbs, Julie E ^a   Ray, David W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MELATONIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREDNISONE; RETINOIC ACID RECEPTOR; RETINOID RELATED ORPHAN RECEPTOR ALPHA; RETINOID RELATED ORPHAN RECEPTOR BETA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR CLOCK; TUMOR NECROSIS FACTOR ALPHA;

CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CHRONOTHERAPY; CIRCADIAN RHYTHM; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; DNA RESPONSIVE ELEMENT; GENE EXPRESSION; HUMAN; IMMUNE SYSTEM; IMMUNOREGULATION; INCIDENCE; IRRITABLE COLON; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ARTHRITIS, RHEUMATOID; CIRCADIAN CLOCKS; CIRCADIAN RHYTHM; HUMANS;

EID: 84874108447     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4146     Document Type: Review

References (63)

1. Ingpen ML. The quantitative measurement of joint changes in rheumatoid arthritis. Ann Phys Med 1968, 9:322-327.
2. Perry MG, Kirwan JR, Jessop DS, Hunt LP. Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritis. Ann Rheum Dis 2009, 68:63-68. 2596304, 18375536.
3. Arvidson NG, Gudbjornsson B, Elfman L, Ryden AC, Totterman TH, Hallgren R. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis 1994, 53:521-524. 10.1136/ard.53.8.521, 1005392, 7944637.
4. Albrecht U. Timing to perfection: the biology of central and peripheral circadian clocks. Neuron 2012, 74:246-260. 10.1016/j.neuron.2012.04.006, 22542179.
5. Relogio A, Westermark PO, Wallach T, Schellenberg K, Kramer A, Herzel H. Tuning the mammalian circadian clock: robust synergy of two loops. PLoS Comput Biol 2011, 7:e1002309. 10.1371/journal.pcbi.1002309, 3240597, 22194677.
6. Keller M, Mazuch J, Abraham U, Eom GD, Herzog ED, Volk HD, Kramer A, Maier B. A circadian clock in macrophages controls inflammatory immune responses. Proc Natl Acad Sci USA 2009, 106:21407-21412. 10.1073/pnas.0906361106, 2795539, 19955445.
7. Bollinger T, Leutz A, Leliavski A, Skrum L, Kovac J, Bonacina L, Benedict C, Lange T, Westermann J, Oster H, Solbach W. Circadian clocks in mouse and human CD4+ T cells. PLoS One 2011, 6:e29801. 10.1371/journal.pone.0029801, 3247291, 22216357.
8. Wang X, Reece SP, Van Scott MR, Brown JM. A circadian clock in murine bone marrow-derived mast cells modulates IgE-dependent activation in vitro. Brain Behav Immun 2011, 25:127-134. 10.1016/j.bbi.2010.09.007, 20854894.
9. Fortier EE, Rooney J, Dardente H, Hardy MP, Labrecque N, Cermakian N. Circadian variation of the response of T cells to antigen. J Immunol 2011, 187:6291-6300. 10.4049/jimmunol.1004030, 22075697.
10. Gibbs JE, Blaikley J, Beesley S, Matthews L, Simpson KD, Boyce SH, Farrow SN, Else KJ, Singh D, Ray DW, Loudon AS. The nuclear receptor REV-ERBalpha mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. Proc Natl Acad Sci USA 2012, 109:582-587. 10.1073/pnas.1106750109, 3258648, 22184247.
11. Haas S, Straub RH. Disruption of rhythms of molecular clocks in primary synovial fibroblasts of patients with osteoarthritis and rheumatoid arthritis, role of IL-1beta/TNF. Arthritis Res Ther 2012, 14:R122. 10.1186/ar3852, 3446503, 22621205.
12. Coogan AN, Wyse CA. Neuroimmunology of the circadian clock. Brain Res 2008, 1232:104-112.
13. Wang XS, Armstrong ME, Cairns BJ, Key TJ, Travis RC. Shift work and chronic disease: the epidemiological evidence. Occup Med (Lond) 2011, 61:78-89. 10.1093/occmed/kqr001, 3045028, 21355031.
14. Castanon-Cervantes O, Wu M, Ehlen JC, Paul K, Gamble KL, Johnson RL, Besing RC, Menaker M, Gewirtz AT, Davidson AJ. Dysregulation of inflammatory responses by chronic circadian disruption. J Immunol 2010, 185:5796-5805. 10.4049/jimmunol.1001026, 2974025, 20944004.
15. Logan RW, Zhang C, Murugan S, O'Connell S, Levitt D, Rosenwasser AM, Sarkar DK. Chronic shift-lag alters the circadian clock of NK cells and promotes lung cancer growth in rats. J Immunol 2012, 188:2583-2591. 10.4049/jimmunol.1102715, 22308312.
16. Puttonen S, Oksanen T, Vahtera J, Pentti J, Virtanen M, Salo P, Kivimaki M. Is shift work a risk factor for rheumatoid arthritis? The Finnish Public Sector study. Ann Rheum Dis 2010, 69:779-780.
17. Hashiramoto A, Yamane T, Tsumiyama K, Yoshida K, Komai K, Yamada H, Yamazaki F, Doi M, Okamura H, Shiozawa S. Mammalian clock gene Cryptochrome regulates arthritis via proinflammatory cytokine TNF-alpha. J Immunol 2010, 184:1560-1565. 10.4049/jimmunol.0903284, 20042581.
18. Narasimamurthy R, Hatori M, Nayak SK, Liu F, Panda S, Verma IM. Circadian clock protein cryptochrome regulates the expression of proinflammatory cytokines. Proc Natl Acad Sci USA 2012, 109:12662-12667. 10.1073/pnas.1209965109, 3411996, 22778400.
19. Radogna F, Diederich M, Ghibelli L. Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmacol 2010, 80:1844-1852. 10.1016/j.bcp.2010.07.041, 20696138.
20. Nah SS, Won HJ, Park HJ, Ha E, Chung JH, Cho HY, Baik HH. Melatonin inhibits human fibroblast-like synoviocyte proliferation via extracellular signal-regulated protein kinase/P21(CIP1)/P27(KIP1) pathways. J Pineal Res 2009, 47:70-74. 10.1111/j.1600-079X.2009.00689.x, 19538337.
21. Sulli A, Maestroni GJ, Villaggio B, Hertens E, Craviotto C, Pizzorni C, Briata M, Seriolo B, Cutolo M. Melatonin serum levels in rheumatoid arthritis. Ann NY Acad Sci 2002, 966:276-283. 10.1111/j.1749-6632.2002.tb04227.x, 12114284.
22. Hansson I, Holmdahl R, Mattsson R. The pineal hormone melatonin exaggerates development of collagen-induced arthritis in mice. J Neuroimmunol 1992, 39:23-30. 10.1016/0165-5728(92)90171-G, 1619037.
23. Hansson I, Holmdahl R, Mattsson R. Pinealectomy ameliorates collagen II-induced arthritis in mice. Clin Exp Immunol 1993, 92:432-436. 1554762, 8513575.
24. Forrest CM, Mackay GM, Stoy N, Stone TW, Darlington LG. Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Br J Clin Pharmacol 2007, 64:517-526. 10.1111/j.1365-2125.2007.02911.x, 2048559, 17506781.
25. Cutolo M, Straub RH, Buttgereit F. Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside. Ann Rheum Dis 2008, 67:905-908.
26. Surjit M, Ganti KP, Mukherji A, Ye T, Hua G, Metzger D, Li M, Chambon P. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 2011, 145:224-241. 10.1016/j.cell.2011.03.027, 21496643.
27. McMaster A, Ray DW. Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects. Exp Physiol 2007, 92:299-309. 10.1113/expphysiol.2006.036194, 17138619.
28. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med 2005, 353:1711-1723. 10.1056/NEJMra050541, 16236742.
29. Uhlenhaut NH, Barish GD, Yu RT, Downes M, Karunasiri M, Liddle C, Schwalie P, Hubner N, Evans RM. Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes. Mol Cell 2013, 49:1-14.
30. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008, 4:525-533.
31. Yang X, Downes M, Yu RT, Bookout AL, He W, Straume M, Mangelsdorf DJ, Evans RM. Nuclear receptor expression links the circadian clock to metabolism. Cell 2006, 126:801-810. 10.1016/j.cell.2006.06.050, 16923398.
32. Bechtold DA, Gibbs JE, Loudon AS. Circadian dysfunction in disease. Trends Pharmacol Sci 2010, 31:191-198. 10.1016/j.tips.2010.01.002, 20171747.
33. Charmandari E, Chrousos GP, Lambrou GI, Pavlaki A, Koide H, Ng SS, Kino T. Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. PLoS One 2011, 6:e25612. 10.1371/journal.pone.0025612, 3182238, 21980503.
34. Lamia KA, Papp SJ, Yu RT, Barish GD, Uhlenhaut NH, Jonker JW, Downes M, Evans RM. Cryptochromes mediate rhythmic repression of the glucocorticoid receptor. Nature 2011, 480:552-556. 3245818, 22170608.
35. McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133. 10.1016/j.cell.2006.07.035, 16990136.
36. Kopmels B, Mariani J, Delhaye-Bouchaud N, Audibert F, Fradelizi D, Wollman EE. Evidence for a hyperexcitability state of staggerer mutant mice macrophages. J Neurochem 1992, 58:192-199. 10.1111/j.1471-4159.1992.tb09295.x, 1727430.
37. Delerive P, Monte D, Dubois G, Trottein F, Fruchart-Najib J, Mariani J, Fruchart JC, Staels B. The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response. EMBO Rep 2001, 2:42-48. 10.1093/embo-reports/kve007, 1083804, 11252722.
38. Journiac N, Jolly S, Jarvis C, Gautheron V, Rogard M, Trembleau A, Blondeau JP, Mariani J, Vernet-der GB. The nuclear receptor ROR(alpha) exerts a bi-directional regulation of IL-6 in resting and reactive astrocytes. Proc Natl Acad Sci USA 2009, 106:21365-21370. 10.1073/pnas.0911782106, 2795519, 19955433.
39. Eberl G, Littman DR. The role of the nuclear hormone receptor RORgammat in the development of lymph nodes and Peyer's patches. Immunol Rev 2003, 195:81-90. 10.1034/j.1600-065X.2003.00074.x, 12969312.
40. Kawai M, Green CB, Lecka-Czernik B, Douris N, Gilbert MR, Kojima S, Ackert-Bicknell C, Garg N, Horowitz MC, Adamo ML, Clemmons DR, Rosen CJ. A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-gamma nuclear translocation. Proc Natl Acad Sci USA 2010, 107:10508-10513. 10.1073/pnas.1000788107, 2890788, 20498072.
41. Liu C, Li S, Liu T, Borjigin J, Lin JD. Transcriptional coactivator PGC-1alpha integrates the mammalian clock and energy metabolism. Nature 2007, 447:477-481. 10.1038/nature05767, 17476214.
42. Grimaldi B, Bellet MM, Katada S, Astarita G, Hirayama J, Amin RH, Granneman JG, Piomelli D, Leff T, Sassone-Corsi P. PER2 controls lipid metabolism by direct regulation of PPARgamma. Cell Metab 2010, 12:509-520. 10.1016/j.cmet.2010.10.005, 21035761.
43. Chawla A. Control of macrophage activation and function by PPARs. Circ Res 2010, 106:1559-1569. 10.1161/CIRCRESAHA.110.216523, 2897247, 20508200.
44. Jones DC, Ding X, Daynes RA. Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem 2002, 277:6838-6845. 10.1074/jbc.M106908200, 11726654.
45. Klotz L, Burgdorf S, Dani I, Saijo K, Flossdorf J, Hucke S, Alferink J, Nowak N, Beyer M, Mayer G, Langhans B, Klockgether T, Waisman A, Eberl G, Schultze J, Famulok M, Kolanus W, Glass C, Kurts C, Knolle PA. The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med 2009, 206:2079-2089. 10.1084/jem.20082771, 2757877, 19737866.
46. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000, 164:1364-1371.
47. Harris SG, Phipps RP. Induction of apoptosis in mouse T cells upon peroxisome proliferator-activated receptor gamma (PPAR-gamma) binding. Adv Exp Med Biol 2002, 507:421-425.
48. Gremese E, Ferraccioli G. The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 2011, 10:582-589. 10.1016/j.autrev.2011.04.018, 21539940.
49. Johnston JD. Adipose circadian rhythms: translating cellular and animal studies to human physiology. Mol Cell Endocrinol 2012, 349:45-50. 10.1016/j.mce.2011.05.008, 21664232.
50. Benedict C, Shostak A, Lange T, Brooks SJ, Schioth HB, Schultes B, Born J, Oster H, Hallschmid M. Diurnal rhythm of circulating nicotinamide phosphoribosyltransferase (Nampt/visfatin/PBEF): impact of sleep loss and relation to glucose metabolism. J Clin Endocrinol Metab 2012, 97:E218-222. 10.1210/jc.2011-2241, 22090280.
51. Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Lago F, Gualillo O. What's new in our understanding of the role of adipokines in rheumatic diseases?. Nat Rev Rheumatol 2011, 7:528-536. 10.1038/nrrheum.2011.107, 21808287.
52. Tomita T, Kakiuchi Y, Tsao PS. THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis. Arthritis Res Ther 2006, 8:R7. 10.1186/ar1856, 1526548, 16356194.
53. Song JS, Kim CH, Heo JY, Cho YS. Rosiglitazone reduces a wide range of proinflammatory profiles in synovial fibroblast SW982 under spheroid culture. Immunol Lett 2010, 131:81-88. 10.1016/j.imlet.2010.02.010, 20211202.
54. Lin TH, Tang CH, Wu K, Fong YC, Yang RS, Fu WM. 15-deoxy-Delta(12,14) -prostaglandin-J2 and ciglitazone inhibit TNF-alpha-induced matrix metalloproteinase 13 production via the antagonism of NF-kappaB activation in human synovial fibroblasts. J Cell Physiol 2011, 226:3242-3250. 10.1002/jcp.22685, 21344384.
55. Shahin D, Toraby EE, Abdel-Malek H, Boshra V, Elsamanoudy AZ, Shaheen D. Effect of peroxisome proliferator-activated receptor gamma agonist (pioglitazone) and methotrexate on disease activity in rheumatoid arthritis (experimental and clinical study). Clin Med Insights Arthritis Musculoskelet Disord 2011, 4:1-10. 3040074, 21339857.
56. Matthews L, Berry A, Tersigni M, D'Acquisto F, Ianaro A, Ray D. Thiazolidinediones are partial agonists for the glucocorticoid receptor. Endocrinology 2009, 150:75-86.
57. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:323-330.
58. Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, Istrate MA, Kamenecka TM, Roush WR, Vidović D, Schürer SC, Xu J, Wagoner G, Drew PD, Griffin PR, Burris TP. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 2011, 472:491-494. 10.1038/nature10075, 3148894, 21499262.
59. Hirota T, Lee JW, St John PC, Sawa M, Iwaisako K, Noguchi T, Pongsawakul PY, Sonntag T, Welsh DK, Brenner DA, Doyle FJ 3, Schultz PG, Kay SA. Identification of small molecule activators of cryptochrome. Science 2012, 337:1094-1097. 10.1126/science.1223710, 22798407.
60. Arvidson NG, Gudbjornsson B, Larsson A, Hallgren R. The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis 1997, 56:27-31. 10.1136/ard.56.1.27, 1752253, 9059137.
61. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008, 371:205-214. 10.1016/S0140-6736(08)60132-4, 18207016.
62. Buttgereit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE, Supronik J, Szombati I, Romer U, Witte S, Saag KG. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 2012, 72:204-210. 3553491, 22562974.
63. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis 2010, 69:1275-1280. 10.1136/ard.2009.126888, 2946119, 20542963.